TREA

98043024 - CANTEX

Follow

Information

  • Trademark
  • 98043024
  • Serial Number
    98043024
  • Filing Date
    June 14, 2023
    a year ago
  • Transaction Date
    February 10, 2025
    15 days ago
  • Status Date
    February 07, 2025
    18 days ago
  • Published for Opposition Date
    March 04, 2025
    6 days from now
  • Location Date
    February 07, 2025
    18 days ago
  • Status Code
    681
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    MILLER,AMANDA A
  • Attorney Docket Number
    51849-T02001
    Attorney Name
    Michael J. Belliveau
    Law Office Assigned Location Code
    O60
  • Owners
Information
Mark Drawing Code
4
Mark Identification
CANTEX
Case File Statements
  • GS0051: Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases
  • GS0451: Licensing of pharmaceuticals and drug discovery technologies
  • GS0441: Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses
  • GS0421: Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases
Case File Event Statements
  • 6/17/2023 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 3/12/2024 - 11 months ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/18/2023 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/4/2024 - 11 months ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/12/2024 - 11 months ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 3/12/2024 - 11 months ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/29/2024 - 9 months ago
    8 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG
  • 5/29/2024 - 9 months ago
    7 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR
  • 9/12/2024 - 5 months ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/12/2024 - 5 months ago
    9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 9/12/2024 - 5 months ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/17/2024 - 4 months ago
    13 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 10/17/2024 - 4 months ago
    12 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 10/17/2024 - 4 months ago
    14 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 10/23/2024 - 4 months ago
    16 - WITHDRAWAL OF ATTORNEY GRANTED Type: WOAG
  • 10/23/2024 - 4 months ago
    15 - TEAS WITHDRAWAL OF ATTORNEY RECEIVED Type: WOAR
  • 10/28/2024 - 4 months ago
    19 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 10/28/2024 - 4 months ago
    21 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 10/28/2024 - 4 months ago
    17 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 10/28/2024 - 4 months ago
    20 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 10/28/2024 - 4 months ago
    18 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 12/17/2024 - 2 months ago
    22 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 1/16/2025 - a month ago
    25 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/16/2025 - a month ago
    24 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 1/16/2025 - a month ago
    23 - ASSIGNED TO LIE Type: ALIE
  • 2/6/2025 - 19 days ago
    26 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/7/2025 - 18 days ago
    27 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV